IP Library Granted Patent US 10,300,270
Granted Patent B2
US 10,300,270 · App. 15/664,562 · Granted May 28, 2019

Device and method for the treatment of breathing disorders and cardiac disorders

Inventors: Mark Gelfand (New York, NY); Howard R. Levin (Teaneck, NJ)
Assignee: Respicardia, Inc.
A61N1/0587A61N1/05A61N1/3601A61N1/362
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,300,270
App. No.
15/664,562
Granted
May 28, 2019
Kind
B2
Abstract

The present invention is related to an implantable medical device for treating breathing disorders and cardiac disorders by delivering stimulation energy to the phrenic nerve, hypoglossal nerves and cardiac muscle tissues.

Claims (20)

1. An implantable medical device for treating a patient comprising:

a. a stimulator configured to provide electrical stimulation to a first lead system that includes a first stimulation electrode;

b. the first lead system configured to transvenously place the first stimulation electrode in a first ranine vein near the patient's first hypoglossal nerve;

c. wherein the stimulator is configured to stimulate the hypoglossal nerve using the first stimulation electrode in the first ranine vein.

2. The implantable medical device of claim 1 , further including:

a. a second lead system operatively connected to the stimulator and including a second stimulation electrode;

b. the second lead system configured to transvenously place the second stimulation electrode in a second ranine vein contralateral to the first ranine vein, the second stimulation electrode near a second hypoglossal nerve;

c. wherein the stimulator is configured to stimulate the first and second hypoglossal nerves using the first and second stimulation electrodes in the first and second ranine veins.

3. The implantable medical device of claim 2 , further comprising:

a. a third lead system configured to transvenously place a third stimulation electrode near the patient's phrenic nerve and wherein a processor is further configured to deliver electrical stimulation to the third stimulation electrode near the patient's phrenic nerve.

4. The implantable medical device of claim 3 , the stimulator being configured to provide electrical stimulation to the first and second lead systems slightly before applying electrical stimulation to the third lead system.

5. The implantable medical device of claim 4 , wherein the stimulator is configured to provide the electrical stimulation to the lead systems at a defined interval.

6. The implantable medical device of claim 4 , further comprising an impedance detector configured to sense a respiration cycle, wherein the stimulator is configured to provide electrical stimulation to the lead systems in synchrony with the respiration cycle.

7. The implantable medical device of claim 2 , wherein the stimulator is configured to supply sub threshold stimulation periodically to the first and second lead systems to alter hypoglossal tone to a value near a value of tone during an awake state.

8. The implantable medical device of claim 2 , wherein the stimulator is configured to supply sub threshold stimulation periodically to the first and second lead systems to alter tone, where a level of sub threshold stimulation is selected not to arouse the patient.

9. The implantable medical device of claim 2 , wherein the stimulator is configured to supply sub threshold stimulation periodically to the first and second lead systems to elevate upper airway muscle tone where a level of sub threshold stimulation is selected so that the patient is not aware of stimulation while the patient is awake.

10. The implantable medical device of claim 2 , further comprising an impedance detector configured to sense a respiration cycle, wherein the stimulator is configured to provide electrical stimulation to the first lead system and the second lead system in synchrony with the respiration cycle.

11. The implantable medical device of claim 10 , wherein the stimulator is configured to supply sub threshold stimulation periodically to the first and second lead systems to alter hypoglossal tone to a value near a value of tone during an awake state.

12. The implantable medical device of claim 10 , wherein the stimulator is configured to supply sub threshold stimulation periodically to the first and second lead systems to alter tone, where a level of sub threshold stimulation is selected not to arouse the patient.

13. The implantable medical device of claim 10 , wherein the stimulator is configured to supply sub threshold stimulation periodically to the first and second lead systems to elevate upper airway muscle tone where a level of sub threshold stimulation is selected so that the patient is not aware of stimulation while the patient is awake.

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 056267 FRAME: 0334. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded May 25, 2021
From: RESPICARDIA, INC.
To: ZOLL RESPICARDIA, INC.
Reel/Frame 056366/0506 →
CHANGE OF NAME Recorded May 17, 2021
From: RESPICARDIA, INC.
To: ZOLL RESPICARDIA, INC.
Reel/Frame 056267/0334 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2021
From: GELFAND, MARK; LEVIN, HOWARD
To: CARDIAC CONCEPTS, INC.
Reel/Frame 055716/0194 →
CHANGE OF NAME Recorded Mar 25, 2021
From: CARDIAC CONCEPTS, INC.
To: RESPICARDIA, INC.
Reel/Frame 055727/0783 →
SECURITY INTEREST Recorded Dec 5, 2017
From: RESPICARDIA, INC.
To: ZOLL MEDICAL CORPORATION
Reel/Frame 044298/0216 →
SECURITY INTEREST Recorded Dec 5, 2017
From: RESPICARDIA, INC.
To: CANTOR FITZGERALD SECURITIES, AS AGENT
Reel/Frame 044298/0370 →
Continuity (4)
Continuation 14521647 · Oct 23, 2014
Continuation 12009352 · Jan 18, 2008
Provisional Application 60881695 · Jan 22, 2007
Related Publication 20170326359A1 · Nov 16, 2017
Cited By (3)
US 12,268,877 US 12,403,312 US 12,569,681